PREIMPLANTATION GENETIC TESTING

Policy Number: LABORATORY 026.1 T2
Effective Date: June 1, 2019

Table of Contents

<table>
<thead>
<tr>
<th>Condition/Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONDITIONS OF COVERAGE</td>
<td>1</td>
</tr>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>DEFINITIONS</td>
<td>2</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>2</td>
</tr>
<tr>
<td>DESCRIPTION OF SERVICES</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>2</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>11</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>11</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
<td>13</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>13</td>
</tr>
</tbody>
</table>

Related Policies

- Chromosome Microarray Testing (Non-Oncology Conditions)
- Infertility Diagnosis and Treatment

CONDITIONS OF COVERAGE

Applicable Lines of Business/Products
This policy applies to Oxford Commercial plan membership.

Benefit Type
General benefits package

Referral Required (Does not apply to non-gatekeeper products)
No

Authorization Required (Precertification always required for inpatient admission)
Yes¹

Precertification with Medical Director Review Required
Yes¹

Applicable Site(s) of Service
(If site of service is not listed, Medical Director review is required)
Other

Special Considerations
¹Precertification with review by a Medical Director or their designee is required.

COVERAGE RATIONALE

**Preimplantation Genetic Testing** (PGT) for monogenic/single gene defects (PGT-M) or inherited structural chromosome rearrangements (PGT-SR) is proven and medically necessary using polymerase chain reaction (PCR), next generation sequencing (e.g., chromosomal rearrangements), or chromosomal microarray (e.g., IdentifySGD, HumanKaryoMap) for the following:

- The embryo is at increased risk of a recognized inherited disorder due to one of the following:
  - The parents are carriers of an autosomal recessive disease
  - At least one parent is a carrier of an autosomal dominant, sex-linked, or mitochondrial condition
  - At least one parent is a carrier of a balanced structural chromosome rearrangement
- Human leukocyte antigen (HLA) typing on an embryo in order for the future child to provide bone marrow or blood to treat an affected sibling

**Preimplantation Genetic Testing** (PGT) is unproven and not medically necessary for all other populations and conditions due to insufficient evidence of efficacy. This includes but is not limited to PGT using chromosome microarray (e.g., Spectrum PGS, Spectrum-PGD+PGS), PCR, or next generation sequencing (e.g., NexCCS) for the following:

- Aneuploidy screening (PGT-A)
- Determining gender when the embryo is not at risk for a sex linked disorder
DEFINITIONS

Preimplantation Genetic Testing (PGT): A test performed to analyze the DNA from oocytes or embryos for human leukocyte antigen (HLA)-typing or for determining genetic abnormalities. These include:
- PGT-A - for aneuploidy screening (formerly PGS)
- PGT-M - for monogenic/single gene defects (formerly single-gene PGD)
- PGT-SR - for chromosomal structural rearrangements (formerly chromosomal PGD)
(Zegers-Hochschild et al., 2017)

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81228</td>
<td>Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g., bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)</td>
</tr>
<tr>
<td>81229</td>
<td>Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>

DESCRIPTION OF SERVICES

Genetic counseling is strongly recommended prior to Preimplantation Genetic Testing (PGT) in order to inform persons being tested about the advantages and limitations of the test as applied to their unique situation.

PGT is an analysis performed on an embryo prior to transfer to screen for aneuploidy (PGT-A), deletions and duplications of genomic material, generally referred to as copy number variations (CNVs) or structural rearrangements (PGT-SR) and analysis of single gene or other inherited disorders in an embryo (PGT-M). Use of this technology is hypothesized to increase the success of infertility treatment, especially in women who have worse outcomes due to advanced maternal age, history of recurrent miscarriage, failed in vitro fertilization (IVF) (CDC, 2017) or a balanced chromosome translocation. In addition, it has been explored as a way to enable single embryo transfer (SET) rather than using multiple embryos to increase the odds of having a successful pregnancy without the risk of a multiple gestation.

CLINICAL EVIDENCE

Preimplantation Genetic Testing

In 2016, Chang and colleagues published a review of the outcomes of in vitro fertilization utilizing preimplantation genetic testing (PGT) from 2011-2012 from the United States Assisted Reproductive Technology Surveillance Data (Change et al., 2016). Overall they included 97,069 non-PGT cycles and 9,833 cycles that used PGT in their analysis. Most were for aneuploidy screening (55.6%), 29% were for "other reasons," and 15% were for preventing genetic disease. In the "other reasons" category, only 2% of clinics provided information on the reason for PGT, and it was primarily for gender selection. In 2011, 98% of clinics reporting doing at least one PGT cycle, and in 2012, 100% of reporting clinics had performed PGT cycles. The clinical characteristics between the three groups differed. The aneuploidy screening group tended to be older (>37 years) and had a higher rate of prior miscarriages. As a group, they had fewer miscarriages than other age matched groups in the study, and had a higher chance of a live birth compared to the age matched non-PGT group. They were more likely to have multiple births compared to the non-PGT group. This group was also more likely to have low birth weight babies. The genetic disease group was younger and did not have a history of prior miscarriages. In this group, in women ages 35-37, the adjusted odds of achieving a pregnancy and live birth were lower than the non-PGT group. In all categories, women using PGT who were <35 years old and transferred one embryo, the odds of clinical pregnancy and live birth were lower than compared to the non-PGT group. Information was not available on the PGT techniques used by the different clinics, on biopsy type, protocol to select chromosome abnormalities, number of embryos, embryo morphology, and number of embryos discarded. The authors concluded that PGT might improve outcomes in populations at risk of a genetically affected child,
including aneuploidy, on the basis of family history, but additional data collection and outcome data is necessary to better understand the overall value and effectiveness of PGT. Prospective, randomized studies are needed.

### Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M)

Rechistky and Kuliev (2018) report on the use of PGT to select embryos at risk for inherited cancer syndromes. In their experience through Reproductive Genetics Innovations, cancer was the largest category of PGT-M for conditions with a genetic pre-disposition. In the PGT-M cohort, there were 5037 cycles, resulting in 3669 transfers of 6038 embryos. In the sub-cohort for cancer pre-disposition, there were 24 cancer syndromes reported, which included hereditary breast and ovarian cancer (BRCA1 and BRCA2), Li Fraumeni syndrome (LFD1), and familial adenomatous polyposis (APC). There were 383 at risk couples that underwent 702 PGT cycles. PGT utilized different methodologies depending on the type of mutation and available parental genetic information. Generally, a polar body or embryo biopsy was taken. Mutation testing using direct mutational analysis or linkage with parental haplotyping was performed. Aneuploidy screening using a 24 chromosome single nucleotide polymorphism (SNP) array or next generation sequencing (NGS) was the final step for couples with advanced maternal age. This resulted in 684 embryos in 484 transfer cycles, and 282 pregnancies. Three hundred and sixteen children were born without the cancer predisposition mutations. The authors reported that the inclusion of 24 chromosome aneuploidy screening for advanced maternal age couple increased the pregnancy rate in the PGT-M group from 50% to 70%, and reduced the miscarriage rate from 14% to 9%.

Kubikova et al. (2018) reported on the development of a multiplex polymerase chain reaction (PCR) test for PGT-M of the beta-globin gene (HBB), responsible for beta-thalassemia and sickle cell anemia. The analysis utilized the amplification of overlapping small HBB segments to cover the entire gene, with analysis using next generation sequencing. In addition, 17 closely linked single nucleotide polymorphisms (SNPs) were tested simultaneously to aid in defining haplotypes in combination with HBB sequencing. A validation study on five family trios representing 14 different mutations was conducted, and results were consistent with previously obtained genetic results. Three of the families continued on to using this protocol for PGT-M. One couple had a single cell embryo biopsy at an early cleavage stage, and the other two families had about five cells extracted from the trophocotderm from blastocyst stage embryos. A total of 21 embryos were tested and had successful whole genome amplification, and NGS analysis was successful. Typical karyotyping and linkage analysis was performed simultaneously as a comparison for standard PGT methods. All but one embryo had an average read depth of 1000x for HBB. The single embryo that failed was found to have nullisomy for chromosome 11 where the HBB gene is located. In one couple, there were low call rates and a high allele dropout rate in the standard karyotype method, likely associated with suboptimal amplification after blastocyst biopsy. Results were resolved using linkage analysis of parental SNPs to confirm mutations and haplotypes found in the embryos. The allele drop out was not found in the NGS analysis. The authors concluded that the use of a trophocotderm biopsy with next generation sequencing provided better accuracy than traditional PGT testing. Pregnancy rates, outcomes and confirmation of PGT results post-natally were not reported in this study.

Current technology allows for PGT-M testing for a multitude of single gene disorders, but the efficacy depends on the performance of gene amplification in a small sample, often a single cell. Volozonoka et al. (2018) examined the difference between multiple displacement amplification (MDA) and OmniPlex whole genome amplification when used for comparative genome hybridization (CGH), Sanger sequencing, SNaPshot (single-base extension sequencing) and fragment size analysis. Nine couples at risk for single gene disorders consented to participate in the study. Disease genes involved included ACTA2, HTT, KRT14, ALOX12B, TPPI, GLB1, MTMI, and DMD. A total of 62 embryos were tested, and 1-8 trophoectodermal cells were taken from the outer layer. All embryos survived the extraction. Thirty-nine embryos underwent whole genome amplification using MDA and the remaining went through OmniPlex linear amplification. Amplification detection was determined by capillary electrophoresis. Direct mutation analysis used Sanger sequencing or SNaPshot, and chromosomes were analyzed using CGH. Whole genome amplification, regardless of method, and testing was successful and provided a conclusive result in all embryos. Five unaffected and euploid embryos were transferred, resulting in four clinical pregnancies and the live birth of two healthy children. Key differences were noted, however. The MDA approach to whole genome amplification resulted in heavier DNA strings and resulting electrogamms were clearer, and the base error rate was lower compared to other PCR based approaches. MDA had significant amplification bias that caused high CGH noise. The authors concluded that methodology choice should depend on which downstream analysis is most needed, and both amplification techniques could be used if there are enough embryonic cells available.

Salleveldt et al. (2017) reported on the use of PGT-M using a single blastomere for mitochondrial disorders. Mitochondrial diseases are transmitted only from the mother, and the expression of disease is dependent on the mutation load, meaning the number of mitochondria carrying the mutation compared to the number of wildtype mitochondria present. Prenatal diagnosis has a potential problem in that the mutational load across all tissues may not be able to be identified completely, and therefore the future phenotype of the fetus cannot be predicted easily. PGT-M is the preferred choice for female carriers, as only mutation free embryos can be transferred. If no mutation free embryos are available, embryos with a low mutation load can be transferred, which reduces the risk of an affected child, but cannot eliminate it. To date, two blastomeres have been used in PGT-M for mitochondrial disease to
better predict the mutation load. This has a negative impact on the live birth rate. The authors studied the value of using only one blastomere in a cohort of nine women carrying an m.3243A>G mutation that causes mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS). These women produced 73 embryos that had two or more blastomeres removed from which 294 single blastomeres were analyzed. Only one blastomere was concluded to have a false negative result. This was based on this cell having a mutation load of about 5%, within the range where an embryo transfer might have been considered, but surrounding blastomeres from the same embryo had a higher mutational load of 22-30%. The authors concluded that as the false negative rate was 0.34%, a single blastomere would be sufficient for PGT-M. Pregnancy rates and outcomes were not highlighted by the authors because their goal was determine first if a single cell would provide the correct diagnosis. Single cells were analyzed but excluded from the data reporting, as well as multi-cells, and used for embryo transfer which they feel would confound the data.

PGT-M was first reported in 1990 for sex selection for an X-linked disorder. The field has evolved since then to encompass many genetic diseases, including early and adult onset disorders. Testing for tissue typing also occurs, with the hopes that a baby will be born that can provide a blood or bone marrow transplant for an older affected sibling. Testing for adult onset disorders and tissue typing to rescue an older sibling raises a number of ethical issues. Analysis can be completed with chromosome microarray, polymerase chain reaction (PCR), or next generation sequencing. Technical challenges exist for all methods, such as timing of the biopsy and which cells are biopsied. Collecting too many cells at an early cleavage stage may impact implantation and pregnancy rates, and early stage biopsies may result in poor DNA amplification. Single cell PCR may also result in allele drop out, which occurs in 10-20% of cases. Allele drop out can result in misdiagnosis between carrier and affected embryos. Because PGT-M is using only 1-2 cells, there is additional risk of contamination of the sample with DNA from the technician or even sperm sticking on the zona pellucida. Errors can occur from transfer of the wrong embryo, from mislabeling, and from couples having unprotected sex during the cycle that results in pregnancy, versus the transferred embryo. In 2005, the European Society of Human Reproduction and Embryology (ESHRE) reported on the reanalysis of 940 untransferred embryos and noted that 93.7% of embryos were correctly classified, with a sensitivity of 99.2% and a specificity of 80.9%. Recent ESHRE data suggested that the success rate of pregnancy after PGT-M was similar to other assisted reproduction, with a live birth rate per oocyte retrieved of 24%. Genetic counseling is strongly recommended prior to PGT-M so that couples have a clear understanding of the pros and cons of this approach. (Lee et al., 2017)

Trachoo et al. (2016) reported on the case of a healthy infant born after intracytoplasmic sperm injection-in vitro fertilization (ICSI-IVF) with a preimplantation genetic diagnosis (PGD) to parents who are carriers of the recessive disease pantotenate kinase-associated neurodegeneration (PKAN). Their first child was diagnosed with PKAN due to a PANK2 gene mutation. To avoid this disorder in subsequent offspring, the couple underwent assisted reproduction in order to take advantage of the availability of preimplantation genetic diagnosis. After a single cycle using ICSI-IVF, seven embryos were tested for the familial PANK2 mutation and for aneuploidy. Two were likely affected, three were likely carriers, one was likely unaffected, and one failed genome amplification and was not genotyped. The unaffected embryo was transferred after a freeze-thaw cycle and resulted in a viable pregnancy. Amniocentesis confirmed the PGT results. The pregnancy resulted in a healthy male live birth at 38 weeks. Postnatal testing also confirmed prior testing, and at age 24 months the baby continues with normal growth and development.

Real-time PCR (RT-PCR) was studied as a solution to overcome the challenge of routine molecular analysis of the beta-globin gene in single cells for PGT-M by Vrettou et al. (2004). They created a protocol utilizing a round of PCR to amplify the HBB gene followed by the analysis of mutations using RT-PCR and microsatellite sizing to identify any contamination. The protocol was first validated on 100 single lymphocyte cells from a known beta-thalassemia carrier. PCR failed in one cell, and allele drop out was noted in only one cell as well. A pilot study was conducted in six PGD cycles resulting in 50 blastomeres. The participating couples had HBB mutations and microsatellite analysis that were previously determined using standard genetic testing methods. Results were obtained in 5-6 hours in 46 of the blastomeres, and all results were concordant with standard PGT-M method done simultaneously. Microsatellite analysis found only parental haplotypes, ruling out contamination. One blastomere had an "impossible" genotype and was considered to result from allele drop out. Non-transferred embryos were re-tested and results were concordant with previously obtained results. A total of 27 blastomeres were considered unaffected and 21 were considered suitable and ultimately transferred. Two clinical pregnancies resulted, and one pregnancy resulted in the live birth of twins. Prenatal diagnosis had confirmed the unaffected status of the twins.

Fiorentino et al. (2003) reported on the use of mini-sequencing, a fluorescent based PCR testing method utilizing computer assisted mutation analysis, in PGT-M. In this method, sequencing of the whole PCR product is not needed, only the region of interest, and a common methodology can be used, regardless of the mutations involved. To determine the reliability of this approach, the authors first validated the approach on 50 single lymphocyte cells per PGD case from known carriers, for a total of 650 single cells. Couples were at risk for 55 different genetic diseases, including cystic fibrosis, beta-thalassemia, sickle cell disease, hemophilia A, spinal muscular atrophy and retinoblastoma. Positive amplification was found in 600 cells, with a rate ranging from 88-96%. There were 51
occurrences of allele drop out, which varied by loci and ranged from 6-11%. The method was then tested in 970 blastomeres, obtained from 496 fertilized, cleaving oocytes. Of these, 887 blastomeres had positive gene amplification ranging from 87.6%-93.8%. This method provided results in 856 (96.5%) of tested blastomeres. Allele drop out was found in 86 blastomeres. The current standard of automated sequence analysis was also performed, and results were obtained in only 769 (86.7%) blastomeres. One-hundred and thirty-six non-transferred embryos were dis-associated into 438 blastomeres and re-tested, and the genetic diagnosis was confirmed in all, with similar amplification and allele dropout rates. Fifty five embryos were transferred with a clinical pregnancy rate of 27%. Prenatal diagnosis confirmed the PGT-M results, and ten healthy babies were born.

Preimplantation Genetic Testing for Aneuploidy Screening (PGT-A)

A randomized clinical trial was conducted by Verpoest et al. (2018) to determine if women age 36-40 who used PGT-A of the first and second polar body in intracellular sperm injection (ICSI) cycle to select embryos for transfer had a better live birth rate compared to women who did not have PGT-A. Women were excluded from the study if they had three or more failed IVF cycles, three or more clinical miscarriages, poor response or low ovarian reserve. Three hundred and ninety-six women were enrolled between June 2012 and December 2016 in the multi-center study. Two hundred and five were allocated to the PGT-A group using CGH and 191 were in the non-PGT-A control group. Overall the live birth rate between the two groups was the same, at 24%. Fewer women the PGT-A group experienced a miscarriage, and fewer transfers were needed to achieve the same pregnancy rate. The authors noted that the sample size was smaller than targeted which reduced the power of the study. More studies are needed to evaluate whether the potential benefits outweigh drawbacks such as the impact of prolonged culture times in order to complete the PGT-A testing before transfer.

Zore et al. (2018) compared the outcomes of frozen single embryo transfer between euploid embryos and those with segmental mosaicism. Three hundred and twenty seven women had 377 frozen embryo transfers. All embryos underwent biopsy at the blastocyst stage where two or more cells were taken from the trophoectoderm. CGH was used to determine if embryos were euploid or had segmental mosaicism. Three hundred and fifty seven were euploid, and 20 had segmental mosaicism. The spontaneous miscarriage rate was 18.2% in euploid embryos, compared to 40% in segmental mosaic embryos. Furthermore, the live birth rate for euploid embryos was 53.8%, whereas for segmental mosaics the live birth rate was 30%. The authors concluded that reporting segmental mosaicism was important to help with selection of embryos for transfer, and noted that although reduced, segmental mosaics still had the potential to result in a live birth.

Munne (2018) reported on the outcomes of the 2018 Preimplantation Genetic Diagnosis International Society (PGDIS) conference regarding PGT-A. Studies and data were reviewed at the conference that demonstrated improved pregnancy rates per transfer in experience centers and in women over the age of 35 who utilize PGT-A, but not in younger women. Studies using cell-free embryo DNA in spent media were promising, showing 80-90% concordance with biopsy. Mosaicism in the trophectoderm was a topic of debate, the outcome of which was PGDIS agreeing to update their guidelines. However, the guidelines will still recommend transferring euploid embryos favorably over mosaic embryos.

Friedenthal et al. (2018) evaluated the difference in pregnancy outcomes using NGS compared to CGH in single frozen thawed transferred embryos (STEET) in a retrospective review. A total of 916 STEET cycles from 2014 to 2016 were reviewed, and included 548 NGS cases, and 368 cases using CGH. The outcomes analyzed included implantation rate, live birth rate, and miscarriage rate. The NGS group had a higher implantation rate (72% vs. 65%) than CGH, and a higher live birth rate compared to CGH (62% vs 54%). The miscarriage rate was similar between the two groups. The authors concluded that NGS was better at detecting reduced viability embryos caused by mosaicism, and using NGS may result in better pregnancy outcomes when compared to using CGH.

Gleicher and Orvieto (2017) conducted a comprehensive literature review through January, 2017 on research related to current PGS methodologies and outcomes using comparative chromosome screening on 5-6 day TE biopsies, which they call PGS 2.0. This includes aCGH and SNP-based array technologies. Overall they noted that the literature has a skewed view of clinical utility, and uses embryo transfer as the starting point for measuring success, whereas generally IVF literature uses the initiated IVF cycles as the starting point. When using initiated cycles as a starting point, non-PGS cycles result in a higher live birth rate over PGS cycles. In addition, they report from their analysis that TE mosaicism may be present in at least half of all embryos, and mathematical models suggest that that the likelihood of false negative and positive results is too high to safely determine which embryos should be transferred or not. Their overall conclusion is that PGS 2.0 does not have clinical utility and may in fact reduce live birth rates.

In a 2017 consensus opinion, the European Society of Human Genetics and the European Society for Human Reproduction and Embryology (Harper et al., 2017) reviewed the pros and cons of PGT for PGT-M and PGT-A. The authors noted that randomized controlled trials for PGT-A are lacking, and that what constitutes success in the literature has been defined differently by different authors, creating a situation where it is not possible to conduct a meta-analysis of available literature. The data to date suggests that PGT-A may improve the clinical outcome for
patients with normal ovarian reserve, but more data is needed to determine the validity of PGT-A in other patient populations and at which stage of embryo biopsy.

Barad et al. (2017) conducted a retrospective analysis of the impact of PGT-A on pregnancy outcomes in donor oocyte-recipient cycles. The authors utilized the data obtained between 2005 and 2013 from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System. This database relies on voluntary reporting, and 90% of the US IVF centers participate. In this cohort, first embryo transfers with day 5/6 embryos were reviewed, for a total of 20,616 control cycles and 392 PGT-A cycles. The data showed that the pregnancy and live birth rates were lower in the PGT-A group by 35% when compared to the control group. The authors concluded that PGT-A was not associated with improved odds of pregnancy, live birth or miscarriage rate.

Gleicher et al. (2017) addressed the issue of trophoectoderm mosaicism in a collaboration between The Center for Human Reproduction in New York City and the Center for Studies in Physics and Biology and the Brivanlou Laboratory of Stem Cell Biology and Molecular Embryology using mathematical modeling. As molecular methodologies improve, it has become more apparent that the trophoectoderm has more mosaicism than previously appreciated. Recent studies have shown that over a third of embryos considered to be aneuploid were actually mostly euploid-normal on follow up studies. This has raised concerns about the impact on PGT-A results and whether or not mosaic embryos can be transferred. The authors developed two models to assess the likelihood of false positive and false negative results on an average six cell biopsy from a 300 cell trophoectoderm, with the understanding that trophoectoderm biopsies often include only one cell. The models assumed that mosaicism was distributed evenly throughout the trophoectoderm, even though in reality it is often clonal. In their first model that examined the probability of a false negative with results from one or more euploid cells, they determined that there is a high probability of selecting a euploid cell, even when the ratio of euploid cells is low. In the second model, the probability of a false positive from an aneuploid result was examined. The authors found that even with 1-2 cells being aneuploid, the embryo could theoretically still be mostly euploid. When three cells were found to be aneuploid, it is mathematically more likely consistent with embryo aneuploidy. The author's goal was to examine through mathematical modeling the likely reliability of being able to choose or discard an embryo based on ploidy results of a single cell trophoectoderm biopsy. They concluded that mathematically, one cannot use the results of a single cell to determine the ploidy of an embryo, and therefore cannot reliably predict which embryos should be used or discarded.

To determine the impact on PGT-A on pregnancy rates, Kang et al. (2016) did a retrospective review of outcomes between women utilizing embryo transfer after 24-chromosome PGT-A with women who had fresh, non-biopsied transfers. The cases occurred between 2010 and 2014, and included 274 women who had PGT-A and 863 controls. In women who were < 37 years old, there were no differences in live birth rates between the control and PGT-A group for single or double embryo transfers, and miscarriage rates were similar. In women >37 years old, there was an increase in live birth rates with an odds ratio of 8.2 for women who had a single or double embryo transfer and PGT-A, though the miscarriage rate was the same. When the data was analyzed on a per-retrieval basis, the differences between the control and PGT-A group were no longer significant. The authors concluded that women <37 gained no advantage from using PGT-A, and while the data suggests that it may have some benefit for women>37, the advantage disappears when considered on a per retrieval basis.

The intra-laboratory and intra-embryonic concordance of embryo biopsy aneuploidy was studied by Gleicher et al. (2016). Eleven couples donated an embryo determined to be aneuploid for further research. The embryos were disassociated into 37 anonymized samples and sent to a different national laboratory than originally tested the sample for repeat analysis. Only two of the eleven embryos were found to have identical results between the two labs and were confirmed to be aneuploid. Four embryos were chromosomally normal, two were mosaic, and five were aneuploid, but had different aneuploidies reported between the two labs. In intra-embryo analysis, 50% of the embryos differed between biopsy sites. The authors also note that an additional eight couples chose to transfer aneuploid embryos resulting in five chromosomally normal pregnancies. Four were ongoing pregnancies at the time of publication, and one had a healthy live birth. The authors concluded that trophoectoderm mosaicism may be higher than previously anticipated, and this plus the difference in diagnostic platforms could explain the difference between the two labs. The study size was too small, however, to derive definitive conclusions and more data is needed to assess if a single cell trophoectoderm can be used to select embryos for transfer.

Tortoriello et al. (2016) reported on the comparison of NGS and CGH, as well as intra-laboratory and intra-embryo comparison, on 37 abnormal blastocyst stage embryos. Eight patients donated their embryos for further research after being identified as aneuploid. The embryos were disassociated and sent to two different laboratories for comparison between the labs, CGH and NGS. Only 33% of embryos initially reported to be aneuploid were found to be aneuploid on repeat analysis by CGH. When 27 confirmed aneuploid embryos were re-tested using NGS, 11 (41%) were found to be euploid. Three gender discrepancies between CGH and NGS were found. The authors concluded that such inconsistencies from trophoectoderm biopsies could be due to different sensitivities between platforms and questions the current clinical validity of PGT-A.
Capalbo et al. (2015) compared SNP based microarray screening, aCGH, and qPCR techniques for screening embryos. The authors conducted a prospective double blind observational study from Oct. 2012-Dec. 2013. TE biopsies were done on day 5-6. Forty-five patients were included who had indications of advanced maternal age, recurrent miscarriage, or parental carrier of a balanced translocation. A total of 124 blastocysts underwent aCGH. Of these, 122 survived warming and re-expansion and underwent TE biopsy and qPCR analysis. Two samples failed qPCR and were excluded. Eighty-two percent of embryos showed the same diagnosis between aCGH and qPCR and 18% were discordant for at least one chromosome. Discordant blastocysts were warmed and TE was biopsied again on 21 embryos that survived another rewarming and underwent a blinded SNP array analysis. A conclusive result was obtained in 18 of the 21. In four of these, the qPCR, aCGH, and SNP array did not match and were considered mosaic aneuploid. Overall, when the data is viewed per chromosome, the aCGH and qPCR results were consistent in 99.9% of cases where both methods were performed on TE biopsy from the same embryo. The SNP based reanalysis, however, showed a higher discordant rate between aCGH and qPCR. The authors concluded that TE biopsies can be a highly reliable and effective approach for PGS, and that until aCGH is studied for their clinical negative predictive value, this comparative study can only demonstrate that aCGH results in a higher aneuploidy rate than other contemporary and better validated methods of chromosome screening.

Kurahashi et al. (2015) conducted a comprehensive review of the literature regarding the analytical validity of CMA for PGS. The authors reported that while oligonucleotide arrays (CMA) are the standard for clinical analysis of individuals with developmental delay and congenital anomalies, the need to use a single cell and then perform WGA when using CMA for PGS may introduce amplification bias. Uneven amplification can occur of various regions of the DNA sampled from the embryo and lead to inaccuracy in the test results. Newer technologies including bacterial artificial chromosome (BAC) and a multiple displacement method are being explored as ways to mitigate amplification bias. Mosaicism in the embryo is also reported by the authors as a factor to overcome in using CMA for PGS. It has been demonstrated in the oocyte and blastomere that the spindle assembly process that regulates chromosome segregation is transiently deficient, which leads to a high rate of mosaicism during this stage, and raises the question of whether or not a single cell biopsied during this stage is representative of the whole embryo. In addition, self-correction of the mosaicism to a euploid embryo has been demonstrated, so low level mosaicism may not be a concern. Studies have shown that CMA can identify mosaicism in only 25% of embryos and so may miss low levels of mosaicism. This review further describes issues of cell cycle replication as a confounding factor for CMA. DNA replication begins at more than 10,000 sites in a genome, and during S phase, some parts of the genome have finished replicating and have two copies while other regions have not completed replicating and have a single copy of DNA. This variation in copy number could be incorrectly interpreted as abnormal or as high background noise. The risk of cell cycle issues may be mitigated by performing cell sampling just after cell division, or by trophectoderm biopsy in the blastocyst state. Finally, CMA is not optimal for identifying polyploidy which is a significant limitation because triploidy is one of the most common chromosome abnormalities found in miscarriages. Microarrays that are SNP based can be used for detection of polyploidy, but at the time of publication, SNP arrays have not been optimized for WGA. Overall, the authors conclude that CMA for PGS is slowly becoming a clinical standard, but states that the procedure needs to be optimized on an individual basis and tailored protocols are required.

Novik et al. (2014) published a comparison of fluorescence in situ hybridization (FISH) methods used to evaluate chromosomal mosaicism in IVF embryos with CMA to determine the limits of mosaicism detection, accuracy, and mosaicism prevalence. Chromosomal mosaicism is higher in IVF created embryos than in other prenatal specimens, and may be found in 71-73% of human embryos. Low levels of mosaicism in prenatal specimens suggest selective pressure against mosaic embryos for ongoing pregnancy. Mosaicism has been reported in embryos evaluated by CMA using trophectoderm (TE) biopsies, but the effect of TE mosaicism on development, implantation and pregnancy outcome is unknown. To determine the limits of mosaicism detection, the authors mixed different ratios of amplified DNA from aneuploid and euploid cells, as well as tested clinical samples. Overall, they were able to identify the limit of mosaicism detection with CMA at 25-37% for gains of DNA, and 37-50% for losses. They used the CMA technique developed to CMA was used to determine if an embryo was euploid, non-mosaic aneuploid, or mosaic aneuploid. The diagnostic accuracy of the CMA test was assessed by FISH analysis on non-transferred embryos. In 47 embryos, 26 were considered to be non-mosaic aneuploid by CMA, and 100% were confirmed by FISH. In the mosaic category, 95% were confirmed by FISH. The single embryo not confirmed by FISH did have a discordant result with 7% of nuclei with an aneuploid FISH signal that was below the threshold to call the embryo abnormal. Embryos predicted to the euploid by CMA were not tested by FISH. The authors concluded that CMA testing can identify mosaicism in day 5/6 blastocysts and that FISH confirms that the mosaicism is real and not likely a technical artifact.

Liang et al. (2013) explored the clinical utility of using an oligo microarray for embryo PGS. The team analyzed 383 blastocysts from 72 patients who were advanced maternal age or experience recurrent miscarriage. Biopsied cells underwent Rubicon WGA and screened with an oligo microarray. Some aneuploidy blastocysts were analyzed further by FISH to evaluate the accuracy of results. Overall, 58% of embryos were abnormal. Transfer of normal embryos resulted in an implantation rate of 54%. The FISH and microarray analysis matched in all aneuploid embryos analyzed. The authors concluded that the oligo array platform was able to identify aneuploidy and other small gains and losses, and improved embryo implantation rates.
Yang et al. (2012) studied the value of aCGH in identifying single embryos for transfer. Single embryo transfer (SET) is a strategy utilized by some clinics as a means to reduce the number of multiple gestation pregnancies. In this study, patients included in the study were first time assisted reproduction patients that had normal karyotypes, were < age 35, and seeking elective SET. They were randomized into two groups. Group A had 55 patients who produced 425 blastocysts, and embryos for transfer were selected by morphology and aCGH results. Group B had 48 patients and 389 blastocysts, and embryos were selected based on morphology alone. Amongst the transfers, the clinical pregnancy rate was 71% for Group A, and 46% for Group B. The ongoing pregnancy rate was 69% for Group A, and 42% for Group B. There were no twin pregnancies. Overall, aCGH significantly improved the SET pregnancy rate when compared to using morphology alone.

Liu et al. (2012) utilized a Rubicon WGA kit and an oligo microarray to analyze the pregnancy rate after screening embryos for aneuploidy. They received biopsied cells from the inner cell mass (ICM) or trophoectoderm (TE) for 258 blastocysts from 51 cycles. After microarray, 95% of blastocysts had intact DNA and 57% were aneuploid, with embryos from advanced maternal age women more likely to be abnormal. All euploid embryos survived after warming, and of these, a 63% implantation rate was observed. The authors concluded that using oligo CMA screened embryos can significantly increase the clinical pregnancy rate.

Treff et al. (2011a) studied various whole genome amplification (WGA) techniques in single cells, as accurately amplifying the genome is critical to accurately and successfully genotyping an individual cell. The authors compared three commercially available WGA kits; GenomePlex, REPLI-g, and GenomiPhi, and compared them based on the purpose of the analysis. They specifically studied how well each produced whole genome DNA, and then how well various tests performed; SNP microarray copy number, ability to call individual SNPs, and molecular karyotyping. Human fibroblast cell lines from the Coriell Cell Repository with known karyotypes and genetic results were used. GenomiPhi was able to amplify 88% of single cells yielding >250 ng of DNA, and REPLI-G and GenomePlex yielded >250 ng of DNA in 100% of single cells. REPLI-G provided 88% of genome coverage, and GenomiPhi and GenomePlex provided 74% and 78% respectively. SNP copy number accuracy was 99% for GenomePlex, 95% for REPLI-G, and 62% for GenomiPhi. Chromosome ploidy accuracy was 99% for GenomePlex, 97% for REPLI-G, and 75% for GenomiPhi. The karyotyping diagnostic accuracy was 100% for GenomePlex, 83% for REPLI-G, and 0% for GenomiPhi. This study provides an example of the range of reliability of commercial WGA kits that may be used to predict the reproductive potential and chromosomal status of embryos.

Gutiérrez-Mateo et al. (2011) did an analysis of two aCGH approaches to determine the best method for evaluating single cells in preimplantation genetic screening, and compared aCGH to FISH. Group 1 had WGA with GenomePlex and Group 2 with SurePlex. Results were compared to FISH to determine the error rate. 161 embryos were analyzed in Group 1, and 654 embryos in Group 2. Group 1 had an amplification failure of 11%, and Group 2 was 3%. A total of 66 Group 1 and 54 Group 2 embryos were disaggregated and the remaining cells were analyzed by FISH. The discordance rate between aCGH in Group 1 was 9%, and Group 2 was 2%. Overall, 759 embryos had clear aCGH results regardless if they were Group 1 or 2. 65% of the embryos were classified as abnormal. A comparison of FISH in 120 embryos found that 75% were abnormal, and 44% were mosaic. In reviewing aneuploid events in the cohort, aCGH identified 1615 aneuploid events. FISH would only have found 41% of these with nine probes and 54% with 12 probes. In embryos with two or more abnormalities, 12-chromosome FISH would have identified up to 87% of the abnormal embryos detected by CGH. Implantation rate across both groups was 42%. Overall the authors concluded that CGH will detect 42% more abnormalities and 13% more abnormal embryos as compared to 12-chromosome standard FISH.

Fishel et al. (2011) studied the use of aCGH on analyzing the first oocyte polar body (PB 1) and providing dependable data within 48 hours to support fresh embryo transfer. One hundred and thirty-four couples undergoing IVF participated in the study and inclusion criteria included advanced maternal age, recurrent miscarriage, and previously failed IVF. Polar bodies were biopsied and WGA was accomplished using SurePlex. Of the 134 patients, there were 150 cycles. A total of 861 polar bodies were tested, and 67% were aneuploid. Forty-seven percent of these involved a single chromosome and 26% of cycles failed to results in embryo transfer because there were no euploid oocytes. The live birth rate per embryo transfer was 24%.

Schoolcraft et al. (2010) first used a SNP based microarray to examine all 24 chromosomes for aneuploidy screening as a clinical selection tool for blastocyst transfer for assisted reproduction patients. The authors studied 132 patients who met the inclusion criteria of > 38 years old, recurrent pregnancy loss, or recurrent implantation failure. All embryos were biopsied on day 5 or 6. The authors report that the sensitivity and specificity is 98.6% and 100%, respectively. Ninety-four of the patients produced euploid embryos that were eligible for transfer. Of the 175 embryos transferred, 118 implanted, 111 are ongoing and healthy, or live births. At the time of publication, 28 healthy babies were born to 16 patients. In the transfer group, the biochemical pregnancy rate was 89%, and the clinical pregnancy rate was 77.8%.
Preimplantation Genetic Testing for Chromosomal Structural Rearrangements (PGT-SR)

Next generation sequencing is emerging as an important technique for genetic analysis. Zhou et al. (2018a) examined the validity of using massive parallel sequencing (MPS) on trophoectoderm samples for PGT-A for chromosome translocation carriers. Twelve couples with chromosome translocations participated in a study. Nine had balanced translocations, and three were carriers of a numerical chromosome abnormality. A total of 105 embryos were biopsied on day three and had one cell removed. The cells underwent whole genome amplification, and were then tested for genomic imbalances using MPS and CGH, and confirmed using routine karyotyping. Results were obtained for MPS and CGH for 101 embryos, and there was concordance between MPS and CGH for 19 euploid and 82 unbalanced or aneuploid embryos. There were four discrepancies, however. In one blastomere, MPS found a deletion of an X chromosome not found by CGH. This might be caused by a low density of SNPs on the CGH platform in that region. In another case, MPS identified a 186Mbp duplication on chromosome 1, and a 15.6 Mbp duplication on chromosome 5, whereas CGH identified the duplications but of a different size. This could be related to amplification bias impacting CGH that would have been corrected in the MPS bioinformatics process. In the third embryo, karyotyping and MPS identified an unbalanced translocation between chromosome 3 and 6, and CGH only identified the imbalance in chromosome 3. In the final discrepant embryo, karyotype and MPS identified an unbalanced translocation between chromosomes 13 and 22, and CGH only identified the imbalance in chromosome 13. Twelve of the nineteen embryos that were found to be free of genomic imbalances were used for frozen-thaw embryo transfer, resulting in 1 live birth and 5 ongoing pregnancies.

Brunet, et al. (2018) examined the use of next generation sequencing to identify complex chromosome rearrangements in the embryos of chromosomal translocation carriers. Six couples with complex rearrangements underwent PGT-SR. Biopsies were done on day 5 or 6 blastocysts. A total of 84 oocytes were retrieved, resulting in 25 embryos that had trophoectoderm biopsy and NGS analysis. Vitrified warm embryo transfers were done with six euploid embryos resulting in four healthy live births for four couples. One couple chose to confirm the PGT-SR results with prenatal diagnosis, and the other three did not. Two couples did not have any transferable embryos after two cycles.

Segmental mosaicism is a concern for both PGT-A and PGT-SR. Zhou et al. (2018b) examined the frequency of de novo segmental aneuploidy identified by next generation sequencing (NGS). The study took place over a three year time period and involved 5,735 blastocysts from 1,854 couples who underwent PGT-A (n=770) and PGT-SR (n=1084) on trophoectoderm biopsies. Biopsied cells underwent whole genome amplification using GenomePlex amplification, and low coverage massively parallel sequencing (MPS) on the Proton platform. Overall, 581 blastocysts were found to have 782 de novo segmental aneuploidies. Most carried only one, but 115 had two, and 38 had three or more. There was no association with advanced maternal age or a specific chromosome. In 1,377 cycles, 1,686 blastocysts were transferred resulting in clinical pregnancies in 49% of the PGT-SR group and 47% of the PGT-A group. The miscarriage rate was about 9% in both groups. At the time of publication, there were 84 prenatal diagnosis tests and 645 delivered babies that were considered normal and healthy. Forty blastocysts with de novo segmental aneuploidy were donated for further research, and they were additionally analyzed by FISH as a comparison analysis. Of the donated blastocysts, 39 were successfully analyzed and FISH confirmed the segmental aneuploidy identified by NGS. Because de novo segmental aneuploidy can be caused by either meiosis during gamete formation or during mitosis during embryo development, the trophoectoderm and inner cell mass were evaluated for 26 blastocysts. Five showed pure segmental mosaicism in both the trophoectoderm and inner cell mass, but fourteen showed different levels of mosaicism between the two tissue types. The authors concluded that this analysis showed that segmental de novo aneuploidy is a real issue and is not an artifact of whole genome amplification. Further studies are needed to understand de novo segmental mosaicism and its impact on embryo development.

Maithripala et al. (2018) reviewed the reproductive choices of 36 couples who experienced recurrent miscarriage as a result of one member of the couple carrying a balanced chromosome translocation. The couples were identified through a retrospective chart review of 2321 couples seen in a highly specialized reproductive assistance clinic between 2005 and 2013. The pre-diagnosis obstetrical history was obtained and it was similar for all couples. The date of parental diagnosis was identified for each couple, and used in determining the time from diagnosis to live birth as a point of comparison between couples that chose natural conception and those that picked PGD as their reproductive choice. Twenty three couples chose to pursue natural conception, and thirteen chose PDT-SR. In the natural conception group, there were 24 live births with a live birth incidence of 1 birth per 4.09 years, and 74% of women had at least one live birth in the follow up period. In the PGT-SR group, six live births were recorded, reflecting a live birth incidence of 1 birth per 5.63 years, and 38% of women had at least one live birth in the follow up period. There was no significant difference between the groups in post-parental diagnosis miscarriage or live birth rates. It should be noted that in the PGT-SR group, the miscarriage rate did not take into consideration PGT-SR specific variables. There were 8 failed PGT-SR cycles, which included four euploid embryo transfers that did not result in pregnancy. While failed PGT-SR and miscarriage cannot be equated, the authors felt it was meaningful to report as cycle failure represents a significant effort resulting in a failure to achieve a live birth.
Jews et al. (2018) conducted a systematic review of the literature to examine the evidence support the use of PGT-SR in couples who have experienced recurrent miscarriage due to an inherited structural chromosome rearrangement. Meta-analysis was not possible because of significant differences between the studies. The authors identified 20 studies after a comprehensive review of the literature. Live birth was the primary outcome that was analyzed, and secondary outcomes reviewed included miscarriage rate and time to successful pregnancy. A pooled total of 847 couples that conceived naturally had a live birth rate of 25-71%. A pooled total of 562 couples had PGT-SR and had a similar live birth rate of 26-87%. There were no large comparative or randomized studies found. The studies also had different inclusion criteria and some evaluated patients for additional causes of miscarriage, such as auto-immune disease, whereas others did not. Some studies found a lower miscarriage rate in the PGT-SR group, and others did not. Two studies were identified as the best comparative analysis for examining the miscarriage rate and time to live birth post-parental diagnosis, and the studies had conflicting results. One found a lower miscarriage rate in the PGRD group, and the other did not. Both found a similar time to live birth rate for PGT-SR and natural conception.

The ability of NGS to detect complex chromosome rearrangements as compared with CGH was the focus of a study by Chow et al. (2018). The authors used archived whole genome amplified DNA from 342 embryos at risk of genomic imbalance because of translocation or inversion carrier parents. All embryos had been previously analyzed by CGH. There were 287 blastomere biopsies and 55 trophoectoderms biopsies. Over all the concordance rate on abnormal results was 100% between NGS and CGH, regardless of the biopsy type. The concordance in normal embryos was 98% in the blastomere biopsy group, and 79% on trophoectoderms biopsy groups. NGS detected a de novo segmental aneuploidy and low level mosaicism that were not identified by CGH. The authors concluded that NGS was an acceptable technology to use in PGT-SR.

Zhang et al. (2017) examined the utility of using SNP-microarray in families with balanced translocations to accurately identify euploid embryos for transfer. In 68 blastocysts from 11 translocation families, SNP-microarray identified 42 unbalanced or aneuploid embryos, and 26 balanced or normal chromosomes. Ten families became pregnant on the first cycle; one family was successful on cycle three. Amniocentesis on the resulting pregnancies matched the embryo microarray analysis, resulting in a 100% sensitivity and sensitivity in this cohort, but the authors caution that a larger sample size is needed to further validate sensitivity and sensitivity.

Tobler et al. (2014) conducted a retrospective analysis comparing SNP-array and aCGH in 543 embryos from 63 couples, of which one parent carried a reciprocal translocation. Couples were from 16 different fertility centers with samples being analyzed at one lab. SNP-array was used for molecular karyotyping from 2007 to 2011, and from 2011 to 2014 aCGH was used. No embryo was analyzed by both methods. A cell was obtained from the embryo at day 5 or the blastocyst stage and placed in a stabilizing buffer and frozen for transport. Whole genome amplification (WGA) was accomplished for the SNP-array using a phi29 polymerase protocol, and aCGH WGA was done using a Klenow fragment and a modified random priming protocol. Molecular karyotypes were obtained on 92% (498) of the biopsyed embryos. In the 8% (45) samples that failed, WGA failed and was strongly correlated with poor embryo quality. Overall, 45% of embryos were chromosomally normal, and the remaining had translocation errors or aneuploidy. The pregnancy rates were equivalent for SNP (60%) and aCGH (65%). The pregnancy rate was slightly higher if the biopsy was done on blastocysts (65%) vs. cleavage stage embryos (59%). Overall the authors concluded that SNP or aCGH microarray technologies demonstrate equivalent clinical findings that maximize the pregnancy potential in patients with known parental reciprocal chromosome translocations.

Treff et al. (2011b) evaluated the clinical validity of using SNP microarray testing for PGD. Specifically, an Affymetrix 262K SNP microarray was used to identify genomic imbalances in the embryos of 15 patients known to carry balanced chromosome translocations. A total of 19 in vitro fertilization (IVF) treatment cycles with SNP microarray testing were performed for the 15 patients. One patient produced only aneuploid embryos. Two patients became pregnant naturally, and two did not return to the clinic for embryo transfer. Twelve transfers were performed in the remaining ten patients, ten of which produced a biochemical pregnancy (positive beta-human chorionic gonadotropin testing) and nine of which produced a clinical pregnancy (fetal heart beat). Six of these nine delivered a singleton; the remaining three pregnancies were ongoing at the time of publication. Of the six children born, follow-up after delivery was possible for four and revealed no genomic imbalances. Well designed, comparative studies with larger patient populations are needed to further describe clinical outcomes of microarray testing for PGD in patients with balanced translocations.

**Professional Societies**

**American Society for Reproductive Medicine (ASRM)**

The Ethics committee of ASRM published a comprehensive review of the use of PGT-M for adult onset conditions in 2018. The committee concluded that PGT-M for monogenic adult onset conditions is ethical when the condition is serious and no safe, effective interventions are available. Genetic counselors experienced with PGT-M should provide comprehensive counseling to couples considering PGT-M for adult onset diseases. (Ethics Committee of the American Society for Reproductive Medicine, 2018)
American Society for Reproduction Medicine (ASRM)/Society for Assisted Reproductive Technology (SART)

In this joint Practice Committee Opinion from 2018, ASRM and SART state that while some studies have demonstrated higher birth rates after the use of PGT-A and single-embryo transfer, the studies have important limitations. They conclude that the value of PGT-A as a screening test for in vitro fertilization patients has yet to be determined. Large, prospective studies evaluating a variety of approaches to embryo selection are needed to determine the safety and risks of various technologies. (Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, 2018)

Preimplantation Genetic Diagnosis International Society (PGDIS)

The PGDIS position statement on chromosome mosaicism and preimplantation aneuploidy at the blastocyst state states that only a validated next generation sequencing (NGS) platform that can quantitatively measure copy number should be used, and can accurately measure 20% of mosaicism in a known sample. (PGDIS Position Statement on Chromosome Mosaicism and Preimplantation Aneuploidy Testing at the Blastocyst Stage, 2016)

U.S. FOOD AND DRUG ADMINISTRATION (FDA)


Additional Products

180K Oligo Array and SNP+CGH Array (Ambry Genetics Corp.); Cytogenomic SNP Microarray (2003414), Cytogenomic SNP Microarray, Prenatal (2002366), and Cytogenomic SNP Microarrays, Products of Conception (2005633) (ARUP Laboratories); Chromosomal Microarray Analysis – HR (Test #8655), Chromosomal Microarray Analysis HR + SNP Screen (Test #8665), Chromosomal Microarray Analysis – CytoScan HD SNP Array – Non-Tumor (Test #8650), Targeted Chromosomal Microarray Analysis – Prenatal (Test #8656 [Amniocentesis] or #8657 [CVS]), and Expanded Chromosomal Microarray Analysis – Prenatal (Test #8670 [Amniocentesis] or #8671 [CVS]) (Baylor College of Medicine Medical Genetics Laboratories); Whole-Genome Chromosomal Microarray (GenomeDx), Whole-Genome Chromosomal Microarray, Prenatal, and Whole-Genome Chromosomal Microarray, Products of Conception (GeneDx Inc.); Revea SNP Microarray- Pediatric; Revea SNP Microarray – Prenatal, and Revea SNP Microarray – POC (Integrated Genetics); Chromosomal Microarray, Postnatal, Clarisurie Oligo-SNP (Test 16478), Chromosomal Microarray, Prenatal, Clarisurie Oligo-SNP (Test 90927), and Chromosomal Microarray, POC, Clarisurie Oligo-SNP (Test 90929) (Quest Diagnostics Inc.); Signature ChipOS, Signature ChipOS + SNP, Signature PrenatalChipOS, Signature PrenatalChipOS + SNP, Signature PrenatalChipTE, and Signature PrenatalChipTE + SNP (Signature Genomic Laboratories LLC), HumanKaryomap-12 DNA Analysis Kit (Illumina)

REFERENCES

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare national policy that was researched, developed and approved by UnitedHealthcare Medical Technology Assessment Committee. [2019T0597A]


Preimplantation Genetic Testing
UnitedHealthcare Oxford Clinical Policy


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/01/2019</td>
<td>New policy</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting UnitedHealthcare Oxford standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare Oxford reserves the right to modify its Policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice.

The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Oxford Clinical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.